Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans

• Main Authors: Min-Soo Kim (Author), Yoo-Kyung Song (Author), Ji-Soo Choi (Author), Hye Young Ji (Author), Eunsuk Yang (Author), Joon Seok Park (Author), Hyung Sik Kim (Author), Min-Joo Kim (Author), In-Kyung Cho (Author), Suk-Jae Chung (Author), Yoon-Jee Chae (Author), Kyeong-Ryoon Lee (Author)
• Format: Book
• Published: MDPI AG, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Enavogliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor approved for clinical use in South Korea. As SGLT2 inhibitors are a treatment option for patients with diabetes, enavogliflozin is expected to be prescribed in various populations. Physiologically based pharmacokinetic (P...